The PI3K-AKT-mTOR pathway is constitutively activated in many melanomas, leading to increased cell growth, proliferation, and survival [3,4], and mTOR inhibition with Temsirolimus or sirolimus [rapamycin] has antitumor activity in preclinical models of melanoma [5,6]. Here, AKT1 is linked to melanoma.